post mix result aid lower tax rate
share count mark decent usa pharmaci perform coupl
challeng us retail intern compani continu pursue/
expand strateg partnership announc sizabl new cost save
program help allevi margin pressur time integr
progress cash flow provid support oper environ
remain difficult core trends/margin bear watch modestli
trim estim maintain price target ep
mix result revenu roughli line
estim solid perform pharmaci usa busi
vs strhe off-set weak vs
strhe wholesal vs strhe solid top
line off-set higher anticip cost larg driven rite aid
nr invest reimburs pressur divestitur
boot manufactur busi chang loyalti account result
gross margin vs strhe sg in-lin
expect result oper margin shi estim
adjust script volum came touch
estim tie lower volum revenu per script provid off-set
driven outsiz growth specialti despit yoy increas retail
volum growth driven contribut ss sale remain
sluggish tie de-emphasize select product bp
tough yoy comp bp adjust ep came
estim despit benefit lower tax rate share count
sizabl manag initi launch conjunct earn
manag announc launch transform cost manag
program look drive cost savings/increas effici help off-set
margin pressur digit effort smart spend initi
divis optim creat leaner dynam oper model
target annual cost save excess billion end
third year compani alreadi launch zero-bas smart spend
smart organ program well cost save initi chile
mexico market given challeng oper environ
expect on-going margin pressur applaud program
on-going headway across multipl partnership continu focu
broaden omni-channel presenc new strateg partnership
tr target
initi verili alphabet life scienc unit buy squali
partnership first-choic retail pharmaci partner verili two organ
plan collabor number project gear toward improv health outcom patient
chronic condit lower cost care addit compani receiv encourag
initi feedback partnership posit patient respons kansa citi
pilot hold addit labcorp lh buy locat
roll next four year final partnership launch
retail pharmaci wholesal detail retail pharmaci revenu
came estim environ remain challeng constant
currenc basi total sale decreas ex divestitur loyalti account chang ss
pharmaci sale fell ss retail sale pharmaci wholesal revenu
touch driven primarili unfavor currenc translat
cc basi sale increas tie strong emerg market result
detail guidanc reiter estim updat cffo
came estim quarter impact season work capit
invest cost associ acquisit compani also repurchas
share declar quarterli dividend addit manag reiter
full year guidanc includ adjust ep growth cc basi modestli
tweak adjust ep estim
larg reflect result maintain hold rate price target
page
revenu
revenu
revenu
net incom
non-gaap add back tax
adjust net incom
page
inc global leader pharmaceut servic industri
store world-wide includ equiti method invest sizabl wholesale/distribut network
countri compani largest retail pharmaci unit state retail pharmaci
usa divis gener total compani revenu remain sale
come retail intern pharmaci wholesal
bullish underli trend pharmaceut servic expect sever tailwind
age popul util growth increas gener penetr growth specialti drive on-going
growth sector forese futur believ format sever strateg
partnership optum prime tricar demonstr valu compani scale/cap
provid near term volum tailwind reason optim challeng exist
 retail pharmaci busi continu see margin pressur tie sever factor
rate price pressur payer contract increasingli difficult overal retail environ
valuat risk
hold rate price target base stock trade adjust
cash ep roughli in-lin current multipl view compani scale
differenti like compani free cash flow gener view risk/reward balanc
given us pharmaci margin pressur like linger difficult retail environ upsid
risk price target includ better synergi captur stronger core trend aggress
capit deploy downsid risk includ issu integr increas price pressur
compani mention note
laboratori corpor america hold lh buy david macdonald
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
